Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Introduction: Acetyl-CoA Carboxylase (ACC) is an essential rate-limiting enzyme in fatty acid metabolism. For many years, ACC inhibitors have gained great attention for developing therapeutics for various human diseases including microbial infections, metabolic syndrome, obesity, diabetes, and cancer.Areas covered: We present a comprehensive review and update of ACC inhibitors. We look at the current advance of ACC inhibitors in clinical studies and the implications in drug discovery. We searched ScienceDirect (https://www.sciencedirect.com/), ACS (https://pubs.acs.org/), Wiley (https://onlinelibrary.wiley.com/), NCBI (https://www.ncbi.nlm.nih.gov/) and World Health Organization (https://www.who.int/). The keywords used were Acetyl-CoA Carboxylase, lipid, inhibitors and metabolic syndrome. All documents were published before June 2019.Expert opinion: The key regulatory role of ACC in fatty acid synthesis and oxidation pathways makes it an attractive target for various metabolic diseases. In particular, the combination of ACC inhibitors with other drugs is a new strategy for the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Expanding the clinical indications for ACC inhibitors will be one of the hot directions in the future. It is also worth looking forward to exploring safe and efficient inhibitors that act on the BC domain of ACC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular Fatty Acid Metabolism and Cancer
Currie, E., Schulze, A., Zechner, R., Walther, T. C., & Farese, R. V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.017 · Cited by 2,123
Seravalle, G., & Grassi, G. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.013 · Cited by 909
Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2
Abu-Elheiga, L., Matzuk, M. M., Abo-Hashema, K. A. H., & Wakil, S. J. (2001) · Science · doi:10.1126/science.1056843 · Cited by 903 · cited 1×
“For ACC2 mutant mice (ACC2 -/-), there was no difference in lifespan and insulin levels when fed on a high-fat and high-sugar diet compared to wild-type mice, but their fatty acids and glucose oxidation in the adipose tissues were increased [22,23].”
BackgroundKim, C.-W., Addy, C., Kusunoki, J., Anderson, N. N., Deja, S., Fu, X., Burgess, S. C., Li, C., Ruddy, M., Chakravarthy, M., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.009 · Cited by 419 · cited 9×
“Unlike another ACC inhibitor MK-4074 [60], GS-0976 elevated TG peaked at one week, then spontaneously subsided, and its cardiovascular risk needs further study [76].”
BackgroundInfluentialAbu-Elheiga, L., Oh, W., Kordari, P., & Wakil, S. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1733877100 · Cited by 389 · cited 1×
“Glucose transporter 4 (GLUT4) mRNA and uncoupling protein (UCP) mRNA were significantly increased in ACC2 -/- mice, which was believed to facilitate the mutant mice resistant to glucose-induced obesity and diabetes [24].”
BackgroundChoi, C. S., Savage, D. B., Kulkarni, A., Yu, X. X., Liu, Z.-X., Morino, K., Kim, S., Distefano, A., Samuel, V. T., Neschen, S., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704213200 · Cited by 383
Acetyl-CoA Carboxylase α Is Essential to Breast Cancer Cell Survival
Chajès, V., Cambot, M., Moreau, K., Lenoir, G. M., & Joulin, V. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1489 · Cited by 347
Loomba, R., Kayali, Z., Noureddin, M., Ruane, P., Lawitz, E. J., Bennett, M., Wang, L., Harting, E., Tarrant, J. M., McColgan, B. J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.027 · Cited by 340 · cited 3×
“The liver stiffness measured by MR elastography (MRE) did not change significantly in each group, but a dose-dependent reduction in the fibrosis marker tissue inhibitor of metalloproteinase 1 (TIMP-1) was observed in patients treated with GS0976 20 mg [73].”
BackgroundMethodResultInfluentialMUNDAY, M. R., CAMPBELL, D. G., CARLING, D., & HARDIE, D. G. (1988) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1988.tb14201.x · Cited by 308 · cited 1×
“ACC2 is mainly expressed in tissues such as heart and skeletal muscle, and its catalyzed production of malonyl-CoA is an inhibitor of CPT-1 (Figure 1) [13].”
BackgroundMalonyl-CoA, a Key Signaling Molecule in Mammalian Cells
Saggerson, D. (2008) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.28.061807.155434 · Cited by 301 · cited 1×
“On the other hand, the direct catalytic product of ACC, malonyl-CoA, is an important signaling molecule in normal cells, which plays an important role in stimulation of B cell insulin secretion by glucose and hypothalamic control of appetite [98].”
BackgroundHarriman, G., Greenwood, J., Bhat, S., Huang, X., Wang, R., Paul, D., Tong, L., Saha, A. K., Westlin, W. F., Kapeller, R., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520686113 · Cited by 287 · cited 4×
“GS-0976 could reduce hepatic steatosis in diet-induced obese rats, increase insulin sensitivity, reduce weight gain without affecting food intake, and relieve dyslipidemia [70].”
BackgroundInfluentialBrusselmans, K., De Schrijver, E., Verhoeven, G., & Swinnen, J. V. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0571 · Cited by 277
Linking diet to acne metabolomics, inflammation, and comedogenesis: an update
Melnik, B. (2015) · Clinical, Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s69135 · Cited by 259 · cited 1×
“Therefore, this study suggests that OG could be a potential drug for the treatment of acne vulgaris [67].”
BackgroundLawitz, E. J., Coste, A., Poordad, F., Alkhouri, N., Loo, N., McColgan, B. J., Tarrant, J. M., Nguyen, T., Han, L., Chung, C., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.042 · Cited by 217 · cited 1×
“Two other clinical studies also confirmed that GS-0976 could inhibit hepatic DNL, improved MRI-PDFF, MRE, and markers of fibrosis [74,75].”
BackgroundNakano, R., Takebe, N., Ono, M., Hangai, M., Nakagawa, R., Yashiro, S., Murai, T., Nagasawa, K., Takahashi, Y., Satoh, J., et al. (2017) · Obesity Science & Practice · doi:10.1002/osp4.97 · Cited by 8
Cited by
The role of lipid metabolic reprogramming in tumor microenvironment
Yang, K., Wang, X., Song, C., He, Z., Wang, R., Xu, Y., Jiang, G., Wan, Y., Mei, J., & Mao, W. (2023) · Theranostics · doi:10.7150/thno.82920 · Cited by 270
Acetyl-CoA metabolism as a therapeutic target for cancer
Chen, G., Bao, B., Cheng, Y., Tian, M., Song, J., Zheng, L., & Tong, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115741 · Cited by 54
Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families
Li, L., Meyer, C., Zhou, Z.-W., Elmezayen, A., & Westover, K. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167626 · Cited by 14
Santos, H. O., & Penha-Silva, N. (2025) · Nutrition · doi:10.1016/j.nut.2024.112617 · Cited by 11
Metadata
- Authors
- Chen, L., Duan, Y., Wei, H., Ning, H., Bi, C., Zhao, Y., Qin, Y., & Li, Y.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2019-08-29
- Volume
- 28
- Issue
- 10
- Pages
- 917-930
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2969860806
- Cited by
- 147
- References
- 16
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.